Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

This study is testing a new type of immune cell therapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma — a type of cancer that usually starts in the adrenal glands — that has come back or stopped responding to standard treatment. **You may be eligible if...** - You are between 12 months and 30 years old (first patients on each dose must be at least 6 years old) - You have been confirmed to have high-risk neuroblastoma that has relapsed or is no longer responding to standard treatments - You have measurable disease that can be tracked - Your organs are functioning well enough to tolerate treatment - You are physically able to participate (able to perform at least some normal activities) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an active uncontrolled infection - You are currently in another experimental treatment trial - You have received a similar cell therapy recently (within the past 8 weeks) - You have HIV, hepatitis B, or hepatitis C infection - You are currently taking systemic steroid medications - You have a serious autoimmune disease requiring immune-suppressing drugs Talk to your doctor to see if this trial is right for you.